Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Buys Arcturus Laser Capture Microdissection Business for $10M

NEW YORK, April 4 (GenomeWeb News) - Molecular Devices has acquired the laser capture microdissection business of Arcturus Biosicence for $10 million in cash, the company said today.
 
Under the terms of the agreement, Molecular Devices acquired Arcturus' LCM-related assets and hired 42 Arcturus employees. LCM operations will immediately move to Molecular Devices' headquarters in Sunnyvale, Calif. The company expects that the acquisition will increase its revenues by $8 million to $10 million this year.
 
"We believe that offering LCM systems with our existing genomics and cellular imaging products is a natural fit for our life sciences research customers as LCM is typically an upstream step for genomic or imaging analysis," said Molecular Devices CEO Joseph Keegan in a company statement. "We also believe that we can improve the distribution of the LCM platform by leveraging our worldwide distribution infrastructure."
 
Arcturus has more than 1,000 LCM systems installed worldwide. The company's LCM platform includes reagents for sample preparation, instrumentation and consumables for visualization and excision, and additional reagents for post-capture processing.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.